Evidence map›Paper›PMID 38899932›Full record

ArticleJournal of virology2024

The interferon-regulated host factor hnRNPA0 modulates HIV-1 production by interference with LTR activity, mRNA trafficking, and programmed ribosomal frameshifting.

Fabian Roesmann, Helene Sertznig, Katleen Klaassen, Alexander Wilhelm, Delia Heininger, Stefanie Heß, Carina Elsner, Rolf Marschalek, Mario L Santiago, Stefan Esser and 3 more

Abstract read
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Viral Modulation of Host Splicing.Annual review of virology · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fabian RoesmannGoethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.ORCID 0000-0002-5749-4406
Helene SertznigInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Katleen KlaassenGoethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.
Alexander WilhelmGoethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.
Delia HeiningerGoethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.
Stefanie HeßGoethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.
Carina ElsnerInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Rolf MarschalekInstitute of Pharmaceutical Biology, Goethe-University, Frankfurt am Main, Hessen, Germany.
Mario L SantiagoDepartment of Medicine, University of Colorado Denver, Aurora, Colorado, USA.ORCID 0000-0001-7792-2706
Stefan EsserInstitute for the Research on HIV and AIDS-associated Diseases University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Kathrin SutterInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.ORCID 0000-0001-6397-6551
Ulf DittmerInstitute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Marek WideraGoethe University Frankfurt, University Hospital, Institute for Medical Virology, Frankfurt, Germany.ORCID 0000-0001-5417-9307

Funding

Role of Type I IFNs in Mucosal HIV-1 Immunity and PathogenesisR01AI134220 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS, WILSON, CARA C. · 2017 to 2021
$2.7M
Deutsche Forschungsgemeinschaft (DFG) DI714/18-2Deutsche Forschungsgemeinschaft (DFG) SU1030/1-2Deutsche Forschungsgemeinschaft (DFG) WI 5086/1-1Hessisches Ministerium für Wissenschaft und Kunst (Hessian Ministry for Science and Art) TheraNovaJürgen Manchot Stiftung (Jürgen Manchot Foundation)Medical Faculty of the University of Duisburg EssenNIAID NIH HHS R01 AI134220Wilhelm Sander-Stiftung (Wilhelm Sander Foundation) 2022.070.1
6 · The paper itself

Abstract

The interplay between host factors and viral components impacts viral replication efficiency profoundly. Members of the cellular heterogeneous nuclear ribonucleoprotein family (hnRNPs) have been extensively studied as HIV-1 host dependency factors, but whether they play a role in innate immunity is currently unknown. This study aimed to identify hnRNPA0 as a type I interferon (IFN)-repressed host factor in HIV-1-infected cells. Knockdown of hnRNPA0, a situation that mirrors conditions under IFN stimulation, increased LTR activity, export of unspliced HIV-1 mRNA, viral particle production, and thus, increased infectivity. Conversely, hnRNPA0 overexpression primarily reduced plasmid-driven and integrated HIV-1 long terminal repeat (LTR) activity, significantly decreasing total viral mRNA and protein levels. In addition, high levels of hnRNPA0 significantly reduced the HIV-1 programmed ribosomal frameshifting efficiency, resulting in a shift in the HIV-1 p55/p15 ratio. The HIV-1 alternative splice site usage remained largely unaffected by altered hnRNPA0 levels suggesting that the synergistic inhibition of the LTR activity and viral mRNA transcription, as well as impaired ribosomal frameshifting efficiency, are critical factors for efficient HIV-1 replication regulated by hnRNPA0. The pleiotropic dose-dependent effects under high or low hnRNPA0 levels were further confirmed in HIV-1-infected Jurkat cells. Finally, our study revealed that hnRNPA0 levels in PBMCs were lower in therapy-naive HIV-1-infected individuals compared to healthy controls. Our findings highlight a significant role for hnRNPA0 in HIV-1 replication and suggest that its IFN-I-regulated expression levels are critical for viral fitness allowing replication in an antiviral environment.IMPORTANCERNA-binding proteins, in particular, heterogeneous nuclear ribonucleoproteins (hnRNPs), have been extensively studied. Some act as host dependency factors for HIV-1 since they are involved in multiple cellular gene expression processes. Our study revealed hnRNPA0 as an IFN-regulated host factor, that is differently expressed after IFN-I treatment in HIV-1 target cells and lower expressed in therapy-naïve HIV-1-infected individuals. Our findings demonstrate the significant pleiotropic role of hnRNPA0 in viral replication: In high concentrations, hnRNPA0 limits viral replication by negatively regulating Tat-LTR transcription, retaining unspliced mRNA in the nucleus, and significantly impairing programmed ribosomal frameshifting. Low hnRNPA0 levels as observed in IFN-treated THP-1 cells, particularly facilitate HIV LTR activity and unspliced mRNA export, suggesting a role in innate immunity in favor of HIV replication. Understanding the mode of action between hnRNPA0 and HIV-1 gene expression might help to identify novel therapeutically strategies against HIV-1 and other viruses.

Indexed as

Frameshifting, RibosomalHIV-1HIV InfectionsHIV Long Terminal RepeatRNA, MessengerVirus ReplicationHEK293 CellsHeterogeneous-Nuclear RibonucleoproteinsHost-Pathogen InteractionsHumansJurkat CellsRNA TransportRNA, ViralHeterogeneous-Nuclear RibonucleoproteinsHNRNPA0 protein, humanRNA, MessengerRNA, Viralalternative splicingHIV‑1hnRNPA0IFN-repressed genes (IRepGs)IFN-stimulated genes (ISGs) host dependency factorsprogrammed ribosomal frameshifting (-1PRF)transcriptiontype I interferons (IFN-I)viral replication

Identifiers

PMID38899932
PMCPMC11265465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.